143 related articles for article (PubMed ID: 33395026)
1. Ligand-specific pharmacogenetic effects of nonsynonymous mutations.
Morningstar-Kywi N; Haworth IS; Mosley SA
Pharmacogenet Genomics; 2021 Jun; 31(4):75-82. PubMed ID: 33395026
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants.
Al-Fulaij MA; Ren Y; Beinborn M; Kopin AS
J Mol Neurosci; 2008 Mar; 34(3):211-23. PubMed ID: 18210231
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors.
Liggett SB
Pharmacology; 2000 Sep; 61(3):167-73. PubMed ID: 10971202
[TBL] [Abstract][Full Text] [Related]
4. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of the G protein-coupled receptors.
Thompson MD; Cole DE; Capra V; Siminovitch KA; Rovati GE; Burnham WM; Rana BK
Methods Mol Biol; 2014; 1175():189-242. PubMed ID: 25150871
[TBL] [Abstract][Full Text] [Related]
6. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
[TBL] [Abstract][Full Text] [Related]
7. The G protein-coupled receptors: pharmacogenetics and disease.
Thompson MD; Burnham WM; Cole DE
Crit Rev Clin Lab Sci; 2005; 42(4):311-92. PubMed ID: 16281738
[TBL] [Abstract][Full Text] [Related]
8. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.
Zhang P; Johnson PS; Zöllner C; Wang W; Wang Z; Montes AE; Seidleck BK; Blaschak CJ; Surratt CK
Brain Res Mol Brain Res; 1999 Oct; 72(2):195-204. PubMed ID: 10529478
[TBL] [Abstract][Full Text] [Related]
9. Changes in G protein-coupled receptor sorting protein affinity regulate postendocytic targeting of G protein-coupled receptors.
Thompson D; Pusch M; Whistler JL
J Biol Chem; 2007 Oct; 282(40):29178-85. PubMed ID: 17635908
[TBL] [Abstract][Full Text] [Related]
10. The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.
Fortin JP; Ci L; Schroeder J; Goldstein C; Montefusco MC; Peter I; Reis SE; Huggins GS; Beinborn M; Kopin AS
Mol Pharmacol; 2010 Nov; 78(5):837-45. PubMed ID: 20702761
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists.
Kleinau G; Pratzka J; Nürnberg D; Grüters A; Führer-Sakel D; Krude H; Köhrle J; Schöneberg T; Biebermann H
PLoS One; 2011; 6(10):e27073. PubMed ID: 22073124
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine.
Rosskopf D; Michel MC
Pharmacol Rev; 2008 Dec; 60(4):513-35. PubMed ID: 19074621
[TBL] [Abstract][Full Text] [Related]
13. Implication of the first and third extracellular loops of the mu-opioid receptor in the formation of the ligand binding site: a study using chimeric mu-opioid/angiotensin receptors.
Dietrich G; Gaibelet G; Capeyrou R; Butour JL; Pontet F; Emorine LJ
J Neurochem; 1998 May; 70(5):2106-11. PubMed ID: 9572297
[TBL] [Abstract][Full Text] [Related]
14. Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine.
Tschammer N; Dörfler M; Hübner H; Gmeiner P
ACS Chem Neurosci; 2010 Jan; 1(1):25-35. PubMed ID: 22778805
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.
Bond C; LaForge KS; Tian M; Melia D; Zhang S; Borg L; Gong J; Schluger J; Strong JA; Leal SM; Tischfield JA; Kreek MJ; Yu L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9608-13. PubMed ID: 9689128
[TBL] [Abstract][Full Text] [Related]
16. Overview of Genetic Analysis of Human Opioid Receptors.
Spampinato SM
Methods Mol Biol; 2021; 2201():3-13. PubMed ID: 32975784
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.
Dorn GW; Liggett SB
Clin Transl Sci; 2008 Dec; 1(3):255-62. PubMed ID: 20443857
[TBL] [Abstract][Full Text] [Related]
18. Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL).
Alvarez-Curto E; Prihandoko R; Tautermann CS; Zwier JM; Pediani JD; Lohse MJ; Hoffmann C; Tobin AB; Milligan G
Mol Pharmacol; 2011 Dec; 80(6):1033-46. PubMed ID: 21880827
[TBL] [Abstract][Full Text] [Related]
19. A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.
Sanchez-Soto M; Verma RK; Willette BKA; Gonye EC; Moore AM; Moritz AE; Boateng CA; Yano H; Free RB; Shi L; Sibley DR
Sci Signal; 2020 Feb; 13(617):. PubMed ID: 32019899
[TBL] [Abstract][Full Text] [Related]
20. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.
Johnson JA; Lima JJ
Pharmacogenetics; 2003 Sep; 13(9):525-34. PubMed ID: 12972951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
